Skip to main content

Advertisement

SpringerLink
Log in

Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008

  • CLINICAL TRIAL UPDATES AND HOTLINE SESSIONS
  • Published:
Clinical Research in Cardiology Aims and scope Submit manuscript

Abstract

This article summarizes the results of a number of clinical trials in the field of cardiovascular medicine which were presented during the Hotline and Clinical Trial Update Sessions at the annual meeting of the European Society of Cardiology, held in Munich, Germany, from 30th August to 3rd September 2008. The data were presented by leading experts in the field with relevant positions in the trials. It is important to note that unpublished reports should be considered as preliminary data, as the analysis may change in the final publications. The comprehensive summaries have been generated from the oral presentation and the webcasts of the European Society of Cardiology and should provide the readers with the most comprehensive information on diagnostic and therapeutic developments in cardiovascular medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

3-VD:

Three vessel disease

ACS:

Acute coronary syndrome

ACE-I:

Angiotensin converting enzyme inhibitor

AF:

Atrial fibrillation

AFL:

Atrial flutter

BP:

Blood pressure

bpm:

Beats per minute

CABG:

Coronary artery bypass grafting

CAD:

Coronary artery disease

CHF:

Congestive heart failure

CI:

Confidence interval

CRP:

C-reactive protein

DES:

Drug eluting stents

ECG:

Electrocardiogram

ESC:

European Society of Cardiology

GPIIb/IIIa:

Glycoprotein IIb IIIa

HR:

Hazard ratio

LDL:

Low density lipoprotein

LM:

Left main coronary artery

LVEF:

Left ventricular ejection fraction

MACE:

Major adverse cardiovascular events

MBG:

Myocardial blush grade

MI:

Myocardial infarction

MRI:

Magnetic resonance imaging

NNT:

Number needed to treat

NS:

Not significant

NSTE-ACS:

Non-ST-segment elevation acute coronary syndrome

NSTEMI:

Non-ST-segment elevation myocardial infarction

NYHA:

New York Heart Association

OR:

Odds ratio

PCI:

Percutaneous coronary intervention

RR:

Relative risk

STEMI:

ST-segment elevation myocardial infarction

STR:

ST segment elevation resolution

TVR:

Target vessel revascularization

TIMI:

Thrombolysis in myocardial infarction group

UFH:

Unfractionated heparin

References

  1. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230

    Article  PubMed  CAS  Google Scholar 

  2. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D’Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A (2008) Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118:1172–1182

    Article  PubMed  CAS  Google Scholar 

  3. Fox K, Ford I, Steg PG, Tendera M, Ferrari R (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372:807–816

    Article  PubMed  CAS  Google Scholar 

  4. Reil JC, Böhm M (2007) The role of heart rate in the development of cardiovascular disease. Clin Res Cardiol 96:585–592

    Article  PubMed  Google Scholar 

  5. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet 372:817–821

    Article  PubMed  Google Scholar 

  6. Reil JC, Böhm M (2008) BEAUTIFUL results-the slower, the better? Lancet 372:779–780

    Article  PubMed  Google Scholar 

  7. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M (2006) Management of elderly patients with congestive heart failure—design of the trial of intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Am Heart J 151:949–955

    Article  PubMed  Google Scholar 

  8. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

    Article  PubMed  CAS  Google Scholar 

  9. Clever YP, Rosenkranz S, Böhm M, Scheller B (2008) Hotline update of clinical trials and registries presented at the ACC and SCAI-ACCi2 meeting 2008 in Chicago. Clin Res Cardiol 97:409–417

    Article  PubMed  Google Scholar 

  10. The TRANSCEND Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet. doi:10.1016/SO140-6736(08)61242-8

  11. Ripley TR, Harrison D (2008) The power to TRANSCEND. Lancet. doi:10.1016/SO140-6736(08)61243-X

  12. Yusuf S, Diener HC, Sacco RL et al. for the PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359. doi:10.1056/NEJMoa0804593

  13. GISSI-HF Investigators (2008) Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(08)61241-6.

  14. GISSI-Prevenzione Investigators (1999) Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico. Lancet 354:447–455

    Article  Google Scholar 

  15. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F (2002) Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105:1897–1903

    Article  PubMed  CAS  Google Scholar 

  16. Fonarow GC (2008) Statins and n-3 fatty acid supplementation in heart failure. Lancet. doi:10.1016/S0140-6736(08)61239-8.

  17. van der Harst P, Böhm M, van Gilst WH, van Veldhuisen DJ (2008) The case for statin therapy in chronic heart failure. Clin Res Cardiol 97:139–146

    Article  PubMed  Google Scholar 

  18. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Janosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248–2261

    Article  PubMed  CAS  Google Scholar 

  19. GISSI-HF investigators (2008) Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(08)61241-6.

  20. Rossebo AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R (2008) Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med [Epub ahead of print 2 Sep]

  21. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R (2008) Analyses of cancer data from three ezetimibe trials. N Engl J Med [Epub ahead of print 2 Sep]

  22. Drazen JM, D’Agostino RB, Ware JH, Morrissey S, Curfman GD (2008) Ezetimibe and cancer—an uncertain association. N Engl J Med [Epub ahead of print 2 Sep]

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Kirrberger Straße, 66421, Homburg/Saar, Germany

    Patrick Müller MD, Stephan Rosenkranz, Oliver Adam, Florian Custodis & Michael Böhm

Authors
  1. Patrick Müller MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephan Rosenkranz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Oliver Adam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Florian Custodis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Böhm
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Müller MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Müller, P., Rosenkranz, S., Adam, O. et al. Clinical trial updates and hotline sessions presented at the European Society of Cardiology Congress 2008. Clin Res Cardiol 97, 851–864 (2008). https://doi.org/10.1007/s00392-008-0729-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-008-0729-7

Keywords

Search

Navigation